Core Announcement
AnaptysBio Inc. will release its second‑quarter results on Monday, with the market focusing on whether the company’s royalty‑driven model can offset an anticipated sequential revenue decline.
Financial Highlights
The consensus forecast calls for a net loss of $0.13 per share on revenue of $20.2 million, representing a 21% drop from the prior quarter’s $25.6 million. The prior quarter had posted a loss of $1.84 per share, nearly double the 96‑cent loss analysts had expected, while revenue of $25.6 million beat the $23 million consensus by 11%. Year‑over‑year revenue is projected to fall 9%. The company’s shares trade at $57.29, up from a 52‑week low of $17.11.
Royalty and Pipeline Updates
Jemperli royalty income surged 44% in the first quarter to $24.7 million, supported by the FDA’s acceptance of the drug’s application for priority review in rectal cancer, with a decision slated for February 2027. TD Cowen models a peak U.S. sales potential of approximately $290 million for the rectal cancer indication. The other licensed asset, imsidolimab, developed by Vanda Pharmaceuticals, faces a regulatory decision in December for generalized pustular psoriasis.
Analyst Coverage and Valuation
All 11 analysts covering ANAB rate the stock a Strong Buy, assigning a mean price target of $86.64, which implies a 54% upside from the current price. However, EPS estimates have fallen 53% over the past two months and revenue estimates have declined 14% before stabilising this week. TD Cowen analyst Joseph Thome maintained a Buy rating but reduced his price target to $70 from $75 on August 25.
Capital Allocation
Following the April spin‑off of its drug‑development operations, AnaptysBio announced a $100 million stock repurchase programme. Investors will be watching the execution of the buyback and the broader cash deployment strategy.
Prior Quarter Context
The previous quarter’s earnings missed expectations on the bottom line, with the $1.84 loss per share exceeding the 96‑cent forecast. Revenue of $25.6 million exceeded the $23 million estimate by 11%, driven largely by Jemperli royalty strength, but the earnings shortfall raised concerns about cost management under the transformed royalty‑only model.